Interview with Tom Astle (Tomtec) on the effect of hematocrit in DBS studies
A businessman holding a digital gear icon symbolizing the ETL process in data management, surrounded by related technology icons.
Tom Astle (Tomtec; CT, USA) speaks to Alexandra Sklan at Bioanalysis Zone in October 2012 about the variation in the results generated in two recent hematocrit DBS analytical studies. This interview details the implications of DBS analysis, and how, in the future, it will require significant method development to meet requirements defined by regulatory bodies such as the US FDA. Could you tell Bioanalysis Zone a little about your career to date and how you ended up in engineering bioanalytical applications? While working for the USI film products in 1967, someone detailed the need to automate serial dilution testing. A creative...
